-

Half-year liquidity contract statement for ONXEO

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ONXEO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31, 2022:

- 575,697 shares

- € 10,983.50

- Number of executions on buy side on semester: 349

- Number of executions on sell side on semester: 236

- Traded volume on buy side on semester: 335,452 shares for € 82,028.30

- Traded volume on sell side on semester: 208,189 shares for € 59,090.63

As a reminder:

  • the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:

- 448,434 shares

- € 33,899.60

- Number of executions on buy side on semester: 255

- Number of executions on sell side on semester: 222

- Traded volume on buy side on semester: 269,935 shares for € 99,624.74

- Traded volume on sell side on semester: 251,351 shares for € 96,727.03

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares

- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Contacts

ONXEO

ONXEO

BOURSE:ALONX
Release Versions
EnglishFrench

Contacts

ONXEO

More News From ONXEO

Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter “Valerio Therapeutics” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reports its consolidated half-year financial results to June 30, 2023, and provides an update on its activities. Dr. Shefali Agarwal, President and CEO of Valerio Therapeutics, said: “The first half of 2023 wa...

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023: - 287,160 shares - € 156,554.06 - Number of executions on buy side on semester: 509 - Number of executions on sell side on semester: 492 - Traded volume on buy side on semester: 634,648 shares for € 258,705.74 - Traded volume on sell side on semester: 923,185 shares for € 40...

Onxeo Changes Its Name and Becomes Valerio Therapeutics Following Approval by the Annual General Meeting of June 6, 2023

PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, announced that the Annual General Meeting held today at 2pm CEST was able to validly deliberate with a quorum of 44.12% , with 30 shareholders representing 49,072,091 voting rights. The Annual General Meeting followed the voting rec...
Back to Newsroom